| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kanika Jhanji, Zaitoon Shivji, Marion Lazaj, Lysa Boisse Lomax, Gavin P Winston, Garima Shukl. Quality of life and cannabis use among patients with drug-resistant epilepsy-An observational study from a Canadian tertiary care referral center. Epileptic disorders : international epilepsy journal with videotape. 2024-09-05. PMID:39235763. |
very few publications have reported the impact of artisanal cannabis use on overall quality of life among people with drug-resistant epilepsy. |
2024-09-05 |
2024-09-08 |
Not clear |
| Kanika Jhanji, Zaitoon Shivji, Marion Lazaj, Lysa Boisse Lomax, Gavin P Winston, Garima Shukl. Quality of life and cannabis use among patients with drug-resistant epilepsy-An observational study from a Canadian tertiary care referral center. Epileptic disorders : international epilepsy journal with videotape. 2024-09-05. PMID:39235763. |
this study aimed to evaluate the association of artisanal cannabis use among adults with drug-resistant epilepsy with quality of life, and to determine if an association exists between quality-of-life in epilepsy inventory-31 (qolie-31) 't scores' and different clinical variables. |
2024-09-05 |
2024-09-08 |
Not clear |
| Hamid Abbasi, Mohammad Mehdi Abbasi, Mohammadjavad Pasand, Mahshad Mohtadi, Farnush Bakhshimoghaddam, Ghazaleh Eslamia. Exploring the efficacy and safety of cannabidiol in individuals with epilepsy: an umbrella review of meta-analyses and systematic reviews. Inflammopharmacology. 2024-08-21. PMID:39167312. |
exploring the efficacy and safety of cannabidiol in individuals with epilepsy: an umbrella review of meta-analyses and systematic reviews. |
2024-08-21 |
2024-08-24 |
Not clear |
| Hamid Abbasi, Mohammad Mehdi Abbasi, Mohammadjavad Pasand, Mahshad Mohtadi, Farnush Bakhshimoghaddam, Ghazaleh Eslamia. Exploring the efficacy and safety of cannabidiol in individuals with epilepsy: an umbrella review of meta-analyses and systematic reviews. Inflammopharmacology. 2024-08-21. PMID:39167312. |
cannabidiol (cbd) has received authorization for epilepsy treatment, yet utilizing cbd is linked to a variety of adverse events (aes). |
2024-08-21 |
2024-08-24 |
Not clear |
| Arie Weinstock, E Martina Bebin, Daniel Checketts, Gary D Clark, Jerzy P Szaflarski, Laurie E Seltzer, Elizabeth A Thiele, Farhad Sahebka. Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access program. Epilepsia open. 2024-08-01. PMID:39088193. |
the cannabidiol (cbd) expanded access program provided compassionate access to cbd for patients with treatment-resistant epilepsy, including tuberous sclerosis complex (tsc), at 35 us epilepsy centers. |
2024-08-01 |
2024-08-03 |
Not clear |
| Pukar Khanal, Vishal S Patil, Kunal Bhattacharya, B M Pati. Multifaceted targets of cannabidiol in epilepsy: Modulating glutamate signaling and beyond. Computers in biology and medicine. vol 179. 2024-07-24. PMID:39047503. |
multifaceted targets of cannabidiol in epilepsy: modulating glutamate signaling and beyond. |
2024-07-24 |
2024-07-28 |
Not clear |
| Pukar Khanal, Vishal S Patil, Kunal Bhattacharya, B M Pati. Multifaceted targets of cannabidiol in epilepsy: Modulating glutamate signaling and beyond. Computers in biology and medicine. vol 179. 2024-07-24. PMID:39047503. |
cannabidiol has been reported to interact with broad-spectrum biological targets with pleiotropic pharmacology including epilepsy although a cohesive mechanism is yet to be determined. |
2024-07-24 |
2024-07-28 |
Not clear |
| Pukar Khanal, Vishal S Patil, Kunal Bhattacharya, B M Pati. Multifaceted targets of cannabidiol in epilepsy: Modulating glutamate signaling and beyond. Computers in biology and medicine. vol 179. 2024-07-24. PMID:39047503. |
even though some studies propose that cannabidiol may manipulate glutamatergic signals, there is insufficient evidence to support cannabidiol direct effect on glutamate signaling, which is important in intervening epilepsy. |
2024-07-24 |
2024-07-28 |
Not clear |
| Pukar Khanal, Vishal S Patil, Kunal Bhattacharya, B M Pati. Multifaceted targets of cannabidiol in epilepsy: Modulating glutamate signaling and beyond. Computers in biology and medicine. vol 179. 2024-07-24. PMID:39047503. |
in this study, the epileptic protein targets of cannabidiol were identified using the tanimoto coefficient and similarity index-based targets fishing which were later overlapped with the altered expression, epileptic biomarkers, and genetically altered proteins in epilepsy. |
2024-07-24 |
2024-07-28 |
Not clear |
| Pukar Khanal, Vishal S Patil, Kunal Bhattacharya, B M Pati. Multifaceted targets of cannabidiol in epilepsy: Modulating glutamate signaling and beyond. Computers in biology and medicine. vol 179. 2024-07-24. PMID:39047503. |
glutamate receptor 2 was identified to be genetically varied in epilepsy which was targeted by cannabidiol and its expression was increased with its treatment. |
2024-07-24 |
2024-07-28 |
Not clear |
| Fabrício A Moreira, Antônio C P de Oliveira, Victor R Santos, Márcio F D Morae. Cannabidiol and epilepsy. International review of neurobiology. vol 177. 2024-07-19. PMID:39029983. |
cannabidiol and epilepsy. |
2024-07-19 |
2024-07-22 |
Not clear |
| Rayssa C Briânis, Fabrício A Moreira, Lia P Iglesia. Cannabidiol and addiction. International review of neurobiology. vol 177. 2024-07-19. PMID:39029990. |
cannabidiol (cbd) has been investigated for several therapeutic applications, having reached the clinics for the treatment of certain types of epilepsies. |
2024-07-19 |
2024-07-22 |
Not clear |
| Xin Wang, Haiyan Zhu, Tao Liu, Zhi Guo, Chenyang Zhao, Zhiyi He, Wenxu Zhen. Comparison of various doses of oral cannabidiol for treating refractory epilepsy indications: a network meta-analysis. Frontiers in neurology. vol 15. 2024-07-12. PMID:38994494. |
comparison of various doses of oral cannabidiol for treating refractory epilepsy indications: a network meta-analysis. |
2024-07-12 |
2024-07-14 |
Not clear |
| Xin Wang, Haiyan Zhu, Tao Liu, Zhi Guo, Chenyang Zhao, Zhiyi He, Wenxu Zhen. Comparison of various doses of oral cannabidiol for treating refractory epilepsy indications: a network meta-analysis. Frontiers in neurology. vol 15. 2024-07-12. PMID:38994494. |
to evaluate the comparative efficacy and safety of various doses of oral cannabidiol (cbd) in treating refractory epilepsy indications, thus providing more informative evidence for clinical decision-making. |
2024-07-12 |
2024-07-14 |
Not clear |
| Virginia Brighenti, Matilde Marani, Clarissa Caroli, Laura Bertarini, Alessio Gaggiotti, Federica Pollastro, Caterina Durante, Giuseppe Cannazza, Federica Pellat. A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. Analytical and bioanalytical chemistry. 2024-06-28. PMID:38940871. |
cannabidiol (cbd) is the main non-psychoactive phytocannabinoid derived from cannabis sativa l. it is now an active pharmaceutical ingredient (api), given its usage in treating some types of pediatric epilepsy. |
2024-06-28 |
2024-06-30 |
Not clear |
| Ivan Santos, M Beatriz P P Oliveira, Ana Casas, Javier Fidalgo, Hugo Almeid. Understanding the Potential of CBD for Health Benefits: an Overview. Current drug discovery technologies. 2024-06-07. PMID:38847170. |
cannabidiol (cbd) is a well-known cannabinoid with potential benefits, including reducing epilepsy seizures, alleviating anxiety, and obsessive-compulsive disorder (ocd) symptoms, aiding in tourette syndrome (a neurodevelopmental disorder), depression, sleep disorders, and promising in the treatment of cancer, pain relief, and heart health. |
2024-06-07 |
2024-06-10 |
Not clear |
| Samuel Fernando Vargas Chico, Daniel Alejandro Melendez Diaz, Neyder Contreras-Puente. Use of cannabidiol in the treatment of drug-refractory epilepsy in children and young adults: A systematic review. Journal of neurosciences in rural practice. vol 15. issue 2. 2024-05-16. PMID:38746511. |
use of cannabidiol in the treatment of drug-refractory epilepsy in children and young adults: a systematic review. |
2024-05-16 |
2024-05-27 |
Not clear |
| Maria Concetta Rotolo, Silvia Graziano, Adele Minutillo, Maria Rosaria Varì, Simona Pichini, Emilia Marche. OILVEQ: an Italian external quality control scheme for cannabinoids analysis in galenic preparations of cannabis oil. Clinical chemistry and laboratory medicine. 2024-05-10. PMID:38727000. |
italy legalized cannabis oil for specific medical conditions (neuropathic pain, refractory epilepsy and other established pathologies) in 2015, but mandates titration of principal cannabinoids before marketing each batch using iphenated techniques coupled with mass spectrometry. |
2024-05-10 |
2024-05-27 |
Not clear |
| Federica Pigliasco, Alessia Cafaro, Sebastiano Barco, Manuela Stella, Francesca Mattioli, Antonella Riva, Maria Margherita Mancardi, Simona Lattanzi, Roberto Bandettini, Pasquale Striano, Giuliana Cangem. Innovative LC-MS/MS method for therapeutic drug monitoring of fenfluramine and cannabidiol in the plasma of pediatric patients with epilepsy. Journal of pharmaceutical and biomedical analysis. vol 245. 2024-05-04. PMID:38703746. |
innovative lc-ms/ms method for therapeutic drug monitoring of fenfluramine and cannabidiol in the plasma of pediatric patients with epilepsy. |
2024-05-04 |
2024-05-07 |
human |
| Barbara A Brett, Matthieu Conroy, Hardik Doshi, Matthew X Lowe, Sasha Kalcheff-Korn, Heather Jackso. An observational time-series study on the behavioral effects of adjunctive artisanal cannabidiol use by adults with treatment resistant epilepsies. BMC neurology. vol 24. issue 1. 2024-04-27. PMID:38671370. |
an observational time-series study on the behavioral effects of adjunctive artisanal cannabidiol use by adults with treatment resistant epilepsies. |
2024-04-27 |
2024-04-29 |
Not clear |